Asp2957

Preclinical

Astellas

Asp2957 is one of 4 therapeutic programs targeting X-Linked Myotubular Myopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

X-Linked Myotubular MyopathyNot yet recruiting

X-Linked Myotubular MyopathyPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in X-Linked Myotubular Myopathy

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 3

Rapamune

PPrism Pharmaceuticals

Preclinical

1 4

Asp2957

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

PreclinicalNot yet recruiting

X-Linked Myotubular Myopathy

NCT07876804

Clinical

Trials by Indication[1]

X-Linked Myotubular Myopathy1 trial

A Long-term Study of Young Boys With X-linked Myotubular Myopathy Who Had Previously Received ASP2957

Not yet recruiting· Astellas logo

Astellas·Preclinical·NCT07876804·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Asp2957. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Asp2957. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Astellas

Asp2957

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

X-Linked Myotubular Myopathy1 trial

References

Drug Info

Quick Facts

Related News